Tocilizumab Reduces Depression Risk in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis
Leena Baghdadi
DOI: https://doi.org/10.2147/prbm.s482409
IF: 3.974
2024-10-04
Psychology Research and Behavior Management
Abstract:Leena R Baghdadi Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia Correspondence: Leena R Baghdadi, Email Depression is a possible cause of the increased mental health risks associated with rheumatoid arthritis (RA), including depression-related complications. Biological disease-modifying antirheumatic drug (bDMARDs) therapies have emerged as innovative anti-inflammatory drugs with positive effects on mental well-being. Tocilizumab is a bDMARDs commonly used to treat RA and its influence on depression needs to be studied. It targets interleukin-6 (IL-6) receptors, reducing inflammation, which may also alleviate depressive symptoms due to the role of inflammation in the pathophysiology of depression. Thus, its influence on depression needs to be studied. To assess the strength of the association between exposure to tocilizumab and the rate of development of depression in patients with RA and to evaluate tocilizumab as an exposure and depression as an outcome in these patients, a search was conducted in the MEDLINE, PreMEDLINE, Cochrane, and Scopus databases from January 1980 to April 2024. Inclusion criteria were studies that diagnosed RA according to the latest American College of Rheumatology/European League Against Rheumatism guidelines or a rheumatologist and provided information on tocilizumab exposure and diagnosed depression as an outcome. The present meta-analysis was conducted following the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. These studies were assessed for eligibility by the author and an independent assessor. To summarize the findings, the meta-analysis combined the relative risk estimates from each study with raw data counts. Twelve studies in the meta-analysis fulfilled the inclusion criteria. Tocilizumab monotherapy exhibited a promising beneficial effect on the risk of depression, indicated by the decreased risk in RA patients (Relative risk 0.68, 95% CI 0.20, 2.31). Patients with RA on tocilizumab treatment had a lower risk of developing depression compared to those unexposed to tocilizumab treatment. Therefore, future longitudinal studies are needed to confirm the beneficial effect of tocilizumab on depression in the RA population. Keywords: rheumatoid, Actemra, depression, traditional DMARDs, biologic DMARDs Rheumatoid arthritis (RA) is an inflammatory autoimmune disease estimated to affect 1% of the global adult population. 1 Erosive-destructive RA is characterized by progressive erosion and destruction of joint structures, leading to irreversible joint damage, deformity, functional impairment and disability. Along with physical challenges, many patients with RA experience mental health issues, including depression. 2 The prevalence of anxiety and depressive disorders among patients with RA was 25.1% and 17%, respectively. 2,3 The prevalence of depression in the general population is 5% 2 The incidence rate ratio (IRR) for major depressive disorders significantly increased in patients with incident RA compared to the general population (IRR 1.46, 95% confidence interval [CI] 1.35, 1.58). 4 Uncontrolled depression in patients with RA was associated with several deleterious complications, including an increased risk of disability, reduced physical function and quality of life, and an increased mortality rate. 5 New evidence suggests a common inflammatory pathway between RA and depression. Inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), may be elevated in patients with depressive disorders. 6 Treatments for RA that target TNF inhibitors (TNFi) may improve the mental health outcomes of patients with depression who have chronic physical illnesses 7 and high levels of inflammation. 8 Over the past 25 years, RA management has evolved and is characterized by earlier diagnosis, and earlier, more aggressive treatment. The framework of the "treat-to-target" method emphasizes that the ultimate goal is to reach remission and that medication should be changed until the target is achieved. 9 The typical medical course of action in the early stages of treatment involves administration of traditional synthetic disease-modifying antirheumatic drugs (tDMARDs), predominantly methotrexate (MTX). Targeted biologic DMARDs (bDMARDs), which are more expensive, were previously reserved for patients who did not respond sufficiently to at least two tDMARDs. However, the latest guidelines recommend that adults with active RA should be managed with the intention of achieving remission or minimizing disease activity; if remission is not possible, using the treat-to-target method. This may require the use of multiple tDMARDs and bDMARDs in seq -Abstract Truncated-
psychology, clinical, multidisciplinary